Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • En
  • Sv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance®
    • Oncoral
  • Partnering
  • Investors
    • Press releases
    • Financial reports
    • Presentations & articles
    • Events
    • Share information
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
  • Contact
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2024-08-16 | Ascelia Pharma Announces Prospectus in Connection with Rights Issue
PDF
Report
Presentation
Webcast
Regulatory
2019-02-20 | Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm
PDF
Report
Presentation
Webcast
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Contact

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Ascelia Pharma AB ("Ascelia Pharma" or the “Company") has decided to ...
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start (en)

About us

  • Start (en)
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings
  • IMPORTANT INFORMATION

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all